This article is a retrospective cohort study which compares the survival of patients with type 1 hepatorenal syndrome (HRS) who receive therapy with octreotide and midodrine versus the ones who do not receive it. The combination of octreotide and midodrine has an advantage. However, a randomized controlled study is recommended for more robust evidence.

Link to the article

To quote this article in bibliography:

Esrailian, Eric, Eugene R. Pantangco, Namgyal L. Kyulo, Ke-Qin Hu and Bruce A. Runyon. “Octreotide/Midodrine Therapy Significantly Improves Renal Function and 30-Day Survival in Patients with Type 1 Hepatorenal Syndrome." *Digestive Diseases and Sciences * 52, no. 3 (2007): 742-748. doi: https://doi.org/10.1007/s10620-006-9312-0

Join us in the social media!

Click here to subscribe to our Telegram Channel!

Click here to join to our Telegram Group for discussions